SPI1 (Transcription factor PU.1) variants and mutations
SPI1 (also known as Transcription factor PU.1) is a human protein-coding gene encoding a transcription factor PU.1 protein. It directs transcriptional programs required for myeloid and B-cell development. Altered dosage can block differentiation and cooperate in leukemia, while rare germline variants can cause immunodeficiency or predisposition to myeloid disease. This analysis covers 595 SPI1 variants and mutations. Of these, 81% have computational variant effect predictions. Disease context includes agammaglobulinemia 10, autosomal dominant, agammaglobulinemia, and neurodegenerative disease. Example SPI1 variants include L2F, L2I, and Q3*.
Variant analysis overview
- Gene: SPI1
- Protein: Transcription factor PU.1
- UniProt accession: P17947
- Organism: Homo sapiens
- Variants analyzed: 595
- Variant scope: all variants
- Completed: 2026-08-20
Variant and mutation evidence
- Variant composition: 309 unspecified-consequence records; 4 stop lost; 1 stop retained variant; 162 missense variants; 74 synonymous variants; 27 frameshift variants; 9 stop-gained variants; 7 in-frame deletions; 1 in-frame insertions; 1 protein altering variant
- Prediction scores: 479 variants have prediction scores (81% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: agammaglobulinemia 10, autosomal dominant, agammaglobulinemia, neurodegenerative disease, Alzheimer disease, autosomal agammaglobulinemia, multiple sclerosis, Parkinson disease, lysosomal storage disease, hypertensive disorder, acute myeloid leukemia, essential hypertension, Increased blood pressure.
Protein structure and variant hotspots
- Protein features: 4 binding sites; 2 post-translational modification sites.
- PTM context: 1 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable SPI1 variants
Examples include L2F, L2I, Q3*, Q3E, Q3P, Q3R, A4E, A4T. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- L2F (p.Leu2Phe), TOPMed rs1032809675, gnomAD rs1032809675, REVEL 0.01, MetaLR 0.04, Uncertain significance, not specified
- L2I (p.Leu2Ile), cosmic curated COSV10731, REVEL 0.05, MetaLR 0.07
- Q3* (p.Gln3Ter), ExAC rs759759958, TOPMed rs759759958, gnomAD rs759759958
- Q3E (p.Gln3Glu), ExAC rs759759958, TOPMed rs759759958, gnomAD rs759759958, REVEL 0.05, MetaLR 0.02
- Q3P (p.Gln3Pro), Ensembl rs867961380, REVEL 0.14, MetaLR 0.03
- Q3R (p.Gln3Arg), Ensembl rs867961380
- A4E (p.Ala4Glu), cosmic curated COSV57047, gnomAD rs1273802112, REVEL 0.16, MetaLR 0.09, Uncertain significance, not specified
- A4T (p.Ala4Thr), gnomAD rs1307052870, REVEL 0.04, MetaLR 0.06
- A4V (p.Ala4Val), rs1273802112, NCI-TCGA Cosmic COSV5704, cosmic curated COSV57044, REVEL 0.07, MetaLR 0.08, Variant assessed as somatic; moderate impact.
- C5G (p.Cys5Gly), TOPMed rs2095945146, gnomAD rs2095945146, REVEL 0.15, MetaLR 0.07
- C5Y (p.Cys5Tyr), ExAC rs751720363, gnomAD rs751720363, REVEL 0.12, MetaLR 0.04
- C5S (p.Cys5Ser), gnomAD 11-47355503-C-G, CADD 13.30, SIFT 0.11
- K6N (p.Lys6Asn), Ensembl rs866492257, REVEL 0.07, MetaLR 0.05
- M7I (p.Met7Ile), NCI-TCGA Cosmic COSV5704, cosmic curated COSV57044, Variant assessed as somatic; moderate impact.
- M7K (p.Met7Lys), NCI-TCGA Cosmic COSV9990, cosmic curated COSV99908, Variant assessed as somatic; moderate impact.
- E8K (p.Glu8Lys), NCI-TCGA Cosmic COSV5704, cosmic curated COSV57045, Variant assessed as somatic; moderate impact.
- G9R (p.Gly9Arg), Ensembl rs2142901536
- F10L (p.Phe10Leu), ExAC rs766553435, TOPMed rs766553435, gnomAD rs766553435, REVEL 0.11, MetaLR 0.07, Benign, Agammaglobulinemia
- F10Y (p.Phe10Tyr), TOPMed rs1260363610, gnomAD rs1260363610, REVEL 0.10, MetaLR 0.03
- P11L (p.Pro11Leu), TOPMed rs1000876324
- P11S (p.Pro11Ser), NCI-TCGA Cosmic COSV5704, cosmic curated COSV57047, Variant assessed as somatic; moderate impact.
- L12F (p.Leu12Phe), Ensembl rs2095945127
- L12H (p.Leu12His), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- V13I (p.Val13Ile), cosmic curated COSV57046, ExAC rs763112210, TOPMed rs763112210, gnomAD rs763112210, REVEL 0.04, MetaLR 0.03, Uncertain significance, not specified
- V13T (p.Val13Thr), cosmic curated COSV10505
- P14A (p.Pro14Ala), cosmic curated COSV10505
- P14L (p.Pro14Leu), ExAC rs768484369, gnomAD rs768484369, REVEL 0.06, MetaLR 0.10, Benign, Agammaglobulinemia
- P14S (p.Pro14Ser), cosmic curated COSV10808, REVEL 0.04, MetaLR 0.03
- P15A (p.Pro15Ala), rs771555522, ClinVar RCV005230703, ExAC rs771555522, TOPMed rs771555522, REVEL 0.08, MetaLR 0.10, Benign, Agammaglobulinemia
- P15L (p.Pro15Leu), TOPMed rs1354674575, gnomAD rs1354674575, REVEL 0.10, MetaLR 0.06
- P15R (p.Pro15Arg), TOPMed rs1354674575, gnomAD rs1354674575, REVEL 0.15, MetaLR 0.14
- P15S (p.Pro15Ser), ExAC rs771555522, TOPMed rs771555522, gnomAD rs771555522, REVEL 0.06, MetaLR 0.11, Benign, Agammaglobulinemia
- P15T (p.Pro15Thr), ExAC rs771555522, TOPMed rs771555522, gnomAD rs771555522, REVEL 0.06, MetaLR 0.13, Uncertain significance, not specified
- P16S (p.Pro16Ser), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- S17Y (p.Ser17Tyr), rs1443116093, gnomAD 11-47355530-G-T, CADD 13.10, SIFT 0.00
- D19Y (p.Asp19Tyr), NCI-TCGA Cosmic COSV5704, cosmic curated COSV57044, REVEL 0.22, MetaLR 0.20, Variant assessed as somatic; moderate impact.
- L20Q (p.Leu20Gln), cosmic curated COSV57043
- V21L (p.Val21Leu), gnomAD rs1044667434, REVEL 0.07, MetaLR 0.11, Benign, Agammaglobulinemia
- V21M (p.Val21Met), gnomAD rs1044667434
- P22S (p.Pro22Ser), gnomAD rs2095941390, REVEL 0.03, MetaLR 0.04, Benign, Agammaglobulinemia
- P22T (p.Pro22Thr), cosmic curated COSV57046
- Y23C (p.Tyr23Cys), TOPMed rs1238645940, REVEL 0.34, MetaLR 0.19
- D24N (p.Asp24Asn), gnomAD rs1329451155, REVEL 0.18, MetaLR 0.18, Benign, Agammaglobulinemia
- T25M (p.Thr25Met), NCI-TCGA Cosmic COSV5704, cosmic curated COSV57048, TOPMed rs2095941375, REVEL 0.15, MetaLR 0.11, Benign, Agammaglobulinemia
- D26E (p.Asp26Glu), ExAC rs773070296, gnomAD rs773070296, REVEL 0.03, MetaLR 0.02
- D26G (p.Asp26Gly), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- D26N (p.Asp26Asn), cosmic curated COSV10632
- Q29* (p.Gln29Ter), NCI-TCGA Cosmic COSV9990, cosmic curated COSV99908, Variant assessed as somatic; high impact.
- R30H (p.Arg30His), rs770273178, NCI-TCGA Cosmic COSV5704, cosmic curated COSV57044, ExAC rs770273178, REVEL 0.09, MetaLR 0.08, Benign, Agammaglobulinemia
- R30K (p.Arg30Lys), rs140278101, gnomAD 11-47355533-C-T, CADD 13.30, SIFT 1.00
- T32M (p.Thr32Met), ExAC rs748468072, TOPMed rs748468072, gnomAD rs748468072, REVEL 0.04, MetaLR 0.02, Benign, Agammaglobulinemia
- T32I (p.Thr32Ile), rs1246203109, gnomAD 11-47355488-G-A, CADD 12.70, SIFT 0.08
- H33P (p.His33Pro), cosmic curated COSV57048
- H33Y (p.His33Tyr), rs2495842567, ClinGen CA380359091, ClinVar RCV004464953, REVEL 0.18, MetaLR 0.08, Uncertain significance, not specified
- E34D (p.Glu34Asp), gnomAD rs1257838774
- E34K (p.Glu34Lys), NCI-TCGA Cosmic COSV5704, cosmic curated COSV57045, Ensembl rs2095941337, REVEL 0.08, MetaLR 0.08, Variant assessed as somatic; moderate impact.
- Y36S (p.Tyr36Ser), Ensembl rs1595864404
- Y38H (p.Tyr38His), gnomAD rs1454127715, REVEL 0.14, MetaLR 0.14, Benign, Agammaglobulinemia
- L39I (p.Leu39Ile), NCI-TCGA Cosmic COSV5704, cosmic curated COSV57046, Variant assessed as somatic; moderate impact.
- S40N (p.Ser40Asn), TOPMed rs2095941308
- S40R (p.Ser40Arg), cosmic curated COSV10874, REVEL 0.03, MetaLR 0.05, Benign, Agammaglobulinemia
- S40C (p.Ser40Cys), rs1595853070, gnomAD 11-47355500-G-C, CADD 5.61, SIFT 0.13
- S41T (p.Ser41Thr), gnomAD rs1336660368, REVEL 0.05, MetaLR 0.09, Benign, Agammaglobulinemia
- D42E (p.Asp42Glu), TOPMed rs189217391, gnomAD rs189217391, REVEL 0.07, MetaLR 0.12
- G43A (p.Gly43Ala), ExAC rs755460569, gnomAD rs755460569, REVEL 0.08, MetaLR 0.07, Benign, Agammaglobulinemia
- G43R (p.Gly43Arg), TOPMed rs1162782657, gnomAD rs1162782657, REVEL 0.10, MetaLR 0.11, Benign, Agammaglobulinemia
- E44G (p.Glu44Gly), ExAC rs747515093, gnomAD rs747515093, REVEL 0.11, MetaLR 0.11, Benign, Agammaglobulinemia
- S45R (p.Ser45Arg), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- D48N (p.Asp48Asn), cosmic curated COSV10874, REVEL 0.08, MetaLR 0.11
- H49N (p.His49Asn), cosmic curated COSV10874, REVEL 0.11, MetaLR 0.05
- H49R (p.His49Arg), TOPMed rs1333138894, gnomAD rs1333138894, REVEL 0.08, MetaLR 0.10
- W51* (p.Trp51Ter), cosmic curated COSV57044, CADD 41.00
- F53L (p.Phe53Leu), NCI-TCGA Cosmic COSV9990, cosmic curated COSV99908, REVEL 0.07, MetaLR 0.04, Pathogenic, Agammaglobulinemia
- F53Y (p.Phe53Tyr), TOPMed rs2095918402
- H54P (p.His54Pro), ExAC rs772645546, gnomAD rs772645546, REVEL 0.09, MetaLR 0.04
- H54Q (p.His54Gln), TOPMed rs1003294395, gnomAD rs1003294395, REVEL 0.04, MetaLR 0.04, Benign, Agammaglobulinemia
- H54R (p.His54Arg), ExAC rs772645546, gnomAD rs772645546, REVEL 0.03, MetaLR 0.05
- P55S (p.Pro55Ser), TOPMed rs1300739924, gnomAD rs1300739924, REVEL 0.01, MetaLR 0.03
- P55T (p.Pro55Thr), TOPMed rs1300739924, gnomAD rs1300739924, REVEL 0.02, MetaLR 0.03
- H56T (p.His56Thr), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- H56Y (p.His56Tyr), ExAC rs745879794, TOPMed rs745879794, gnomAD rs745879794, REVEL 0.06, MetaLR 0.09
- H57N (p.His57Asn), TOPMed rs2095918371, gnomAD rs2095918371, REVEL 0.16, MetaLR 0.17, Uncertain significance, not specified
- H57R (p.His57Arg), gnomAD rs1325457780, REVEL 0.17, MetaLR 0.06
- V58M (p.Val58Met), ExAC rs757424163, TOPMed rs757424163, gnomAD rs757424163, REVEL 0.03, MetaLR 0.04, Benign, Agammaglobulinemia
- H59Y (p.His59Tyr), cosmic curated COSV99909, REVEL 0.19, MetaLR 0.07
- S60R (p.Ser60Arg), ExAC rs781009883, TOPMed rs781009883, gnomAD rs781009883, REVEL 0.03, MetaLR 0.04, Benign, Agammaglobulinemia
- E61K (p.Glu61Lys), Ensembl rs2095918344, REVEL 0.13, MetaLR 0.16
- F62L (p.Phe62Leu), ESP rs368215281, ExAC rs368215281, TOPMed rs368215281, gnomAD rs368215281, REVEL 0.08, MetaLR 0.03, Benign, Agammaglobulinemia
- E63D (p.Glu63Asp), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- E63G (p.Glu63Gly), NCI-TCGA TCGA novel, REVEL 0.23, MetaLR 0.14, Variant assessed as somatic; high impact.
- E63K (p.Glu63Lys), ExAC rs766172098, TOPMed rs766172098, gnomAD rs766172098, REVEL 0.20, MetaLR 0.16
- E63Q (p.Glu63Gln), ExAC rs766172098, TOPMed rs766172098, gnomAD rs766172098, REVEL 0.18, MetaLR 0.18
- F65L (p.Phe65Leu), NCI-TCGA Cosmic COSV5704, NCI-TCGA Cosmic COSV9990, cosmic curated COSV99909, Variant assessed as somatic; moderate impact.
- A66P (p.Ala66Pro), ExAC rs113825984, TOPMed rs113825984, gnomAD rs113825984
- A66S (p.Ala66Ser), ExAC rs113825984, TOPMed rs113825984, gnomAD rs113825984, REVEL 0.07, MetaLR 0.02, Benign, Agammaglobulinemia
- A66T (p.Ala66Thr), rs113825984, NCI-TCGA Cosmic COSV5704, cosmic curated COSV57044, ExAC rs113825984, REVEL 0.10, MetaLR 0.03, Benign, Agammaglobulinemia
- A66V (p.Ala66Val), Ensembl rs2095918314
- E67* (p.Glu67Ter), cosmic curated COSV57047, CADD 37.00
- E67D (p.Glu67Asp), TOPMed rs1249261264, gnomAD rs1249261264, NCI-TCGA Cosmic COSV5704, cosmic curated COSV57044, REVEL 0.07, MetaLR 0.04, Benign, Agammaglobulinemia
- E67G (p.Glu67Gly), TOPMed rs1267689361, gnomAD rs1267689361, REVEL 0.05, MetaLR 0.08, Benign, Agammaglobulinemia
- E67K (p.Glu67Lys), cosmic curated COSV99908, TOPMed rs1436543048, gnomAD rs1436543048, REVEL 0.11, MetaLR 0.11, Benign, Agammaglobulinemia
- E67Q (p.Glu67Gln), TOPMed rs1436543048, gnomAD rs1436543048, REVEL 0.10, MetaLR 0.14, Benign, Agammaglobulinemia
- E67R (p.Glu67Arg), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- N69K (p.Asn69Lys), cosmic curated COSV57047, TOPMed rs992345752, REVEL 0.02, MetaLR 0.04
- N69S (p.Asn69Ser), cosmic curated COSV57047
- F70L (p.Phe70Leu), NCI-TCGA TCGA novel, REVEL 0.09, MetaLR 0.04, Variant assessed as somatic; high impact.
- F70V (p.Phe70Val), cosmic curated COSV99908
- F70Y (p.Phe70Tyr), NCI-TCGA Cosmic COSV9990, cosmic curated COSV99908, Variant assessed as somatic; moderate impact.
- T71M (p.Thr71Met), cosmic curated COSV99908, ExAC rs769051484, gnomAD rs769051484, REVEL 0.25, MetaLR 0.18, Benign, Agammaglobulinemia
- E72K (p.Glu72Lys), NCI-TCGA Cosmic COSV5704, cosmic curated COSV57046, Variant assessed as somatic; moderate impact.
- S75N (p.Ser75Asn), TOPMed rs1730387730, REVEL 0.08, MetaLR 0.15
- V76M (p.Val76Met), cosmic curated COSV57044, gnomAD rs1348395847, REVEL 0.18, MetaLR 0.18
- P78F (p.Pro78Phe), cosmic curated COSV57048
- P78S (p.Pro78Ser), ExAC rs772416102, TOPMed rs772416102, gnomAD rs772416102, REVEL 0.05, MetaLR 0.12, Uncertain significance, not specified
- P78T (p.Pro78Thr), rs772416102, NCI-TCGA Cosmic COSV5704, cosmic curated COSV57046, ExAC rs772416102, REVEL 0.11, MetaLR 0.22, Benign, Agammaglobulinemia
- P79L (p.Pro79Leu), ExAC rs746398377, TOPMed rs746398377, gnomAD rs746398377, REVEL 0.09, MetaLR 0.11, Benign, Agammaglobulinemia
- L81R (p.Leu81Arg), gnomAD rs1335120705, Benign, Agammaglobulinemia
- Q83H (p.Gln83His), TOPMed rs767461301, gnomAD rs767461301, REVEL 0.07, MetaLR 0.10
- Y85C (p.Tyr85Cys), NCI-TCGA Cosmic COSV5704, cosmic curated COSV57044, Variant assessed as somatic; moderate impact.
- Y85S (p.Tyr85Ser), gnomAD rs1410522237
- R86C (p.Arg86Cys), TOPMed rs537934199, gnomAD rs537934199, REVEL 0.22, MetaLR 0.11
- R86G (p.Arg86Gly), TOPMed rs537934199, gnomAD rs537934199
- R86H (p.Arg86His), rs1370001180, TOPMed rs1370001180, REVEL 0.15, MetaLR 0.12, Benign, Agammaglobulinemia
- H87R (p.His87Arg), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- M88I (p.Met88Ile), TOPMed rs1385090966
- E89G (p.Glu89Gly), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- L90M (p.Leu90Met), ExAC rs771040203, gnomAD rs771040203, REVEL 0.02, MetaLR 0.06, Benign, Agammaglobulinemia
- E91K (p.Glu91Lys), cosmic curated COSV57047, REVEL 0.13, MetaLR 0.11
- Q92R (p.Gln92Arg), Ensembl rs2095918195, REVEL 0.06, MetaLR 0.13
- H94N (p.His94Asn), TOPMed rs1434340659, gnomAD rs1434340659, REVEL 0.10, MetaLR 0.08, Benign, Agammaglobulinemia
- V95I (p.Val95Ile), rs756375781, ClinGen CA5975530, ClinVar RCV004166167, ClinVar RCV005233112, REVEL 0.06, MetaLR 0.16, Uncertain significance, not specified
- L96F (p.Leu96Phe), TOPMed rs1256771543, gnomAD rs1256771543, REVEL 0.07, MetaLR 0.19
- D97N (p.Asp97Asn), TOPMed rs1595857429, REVEL 0.12, MetaLR 0.19, Benign, Agammaglobulinemia
- T98I (p.Thr98Ile), rs138934569, ClinGen CA5975528, ClinVar RCV004464954, ClinVar RCV005230627, REVEL 0.02, MetaLR 0.06, Uncertain significance, not specified
- P99L (p.Pro99Leu), gnomAD rs1483757482, REVEL 0.06, MetaLR 0.05, Benign, Agammaglobulinemia
- P99T (p.Pro99Thr), TOPMed rs1020808352, gnomAD rs1020808352, REVEL 0.03, MetaLR 0.04
- M100I (p.Met100Ile), NCI-TCGA Cosmic COSV5704, cosmic curated COSV57045, NCI-TCGA Cosmic COSV9990, cosmic curated COSV99909, Variant assessed as somatic; moderate impact.
- M100P (p.Met100Pro), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- M100T (p.Met100Thr), TOPMed rs1209792879, gnomAD rs1209792879, REVEL 0.03, MetaLR 0.05
- M100V (p.Met100Val), ExAC rs758384599, gnomAD rs758384599, REVEL 0.02, MetaLR 0.05, Benign, Agammaglobulinemia
- M100W (p.Met100Trp), rs1265596655, NCI-TCGA Cosmic COSV9990, Variant assessed as somatic; high impact.
- V101L (p.Val101Leu), TOPMed rs2095918116
- P102L (p.Pro102Leu), gnomAD rs1485776430, REVEL 0.05, MetaLR 0.07, Benign, Agammaglobulinemia
- P102S (p.Pro102Ser), cosmic curated COSV57047, REVEL 0.02, MetaLR 0.05
- P103A (p.Pro103Ala), TOPMed rs2095918100
- P103L (p.Pro103Leu), gnomAD rs2095918093, REVEL 0.05, MetaLR 0.06, Benign, Agammaglobulinemia
- H104P (p.His104Pro), rs1595857406, ClinGen CA380352352, ClinVar RCV004464955, REVEL 0.10, MetaLR 0.12, Uncertain significance, not specified
- H104R (p.His104Arg), Ensembl rs1595857406, REVEL 0.12, MetaLR 0.06
- H104Y (p.His104Tyr), ExAC rs750423772, gnomAD rs750423772, REVEL 0.11, MetaLR 0.13, Benign, Agammaglobulinemia
- P105H (p.Pro105His), TOPMed rs1364515194, gnomAD rs1364515194, REVEL 0.07, MetaLR 0.04, Benign, Agammaglobulinemia
- P105S (p.Pro105Ser), NCI-TCGA Cosmic COSV5704, cosmic curated COSV57044, Variant assessed as somatic; moderate impact.
- S106N (p.Ser106Asn), ExAC rs761463108, gnomAD rs761463108, REVEL 0.05, MetaLR 0.07, Benign, Agammaglobulinemia
- L107F (p.Leu107Phe), NCI-TCGA Cosmic COSV9990, cosmic curated COSV99908, REVEL 0.09, MetaLR 0.12, Variant assessed as somatic; moderate impact.
- L107P (p.Leu107Pro), Ensembl rs2095918063
- G108S (p.Gly108Ser), gnomAD rs1280079647, REVEL 0.03, MetaLR 0.03, Benign, Agammaglobulinemia
- H109Q (p.His109Gln), TOPMed rs1050233603, gnomAD rs1050233603, REVEL 0.09, MetaLR 0.09, Benign, Agammaglobulinemia
- Q110* (p.Gln110Ter), rs2142884393, ClinGen CA380352265, ClinVar RCV001353142, ClinVar RCV001819971, Pathogenic
- V111A (p.Val111Ala), Ensembl rs2095916630, REVEL 0.12, AlphaMissense 0.76
- V111I (p.Val111Ile), cosmic curated COSV10505, REVEL 0.09, MetaLR 0.17
- S112T (p.Ser112Thr), TOPMed rs2095916618, REVEL 0.02, MetaLR 0.04
- Y113C (p.Tyr113Cys), ESP rs376045381, ExAC rs376045381, TOPMed rs376045381, gnomAD rs376045381, REVEL 0.06, MetaLR 0.08, Uncertain significance, not specified
- L114P (p.Leu114Pro), gnomAD rs1213069874, REVEL 0.11, MetaLR 0.11
- L114V (p.Leu114Val), TOPMed rs1292107582, gnomAD rs1292107582, REVEL 0.01, MetaLR 0.03, Benign, Agammaglobulinemia
- P115L (p.Pro115Leu), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- R116L (p.Arg116Leu), cosmic curated COSV99909, REVEL 0.10, MetaLR 0.12
- R116Q (p.Arg116Gln), ExAC rs769953805, TOPMed rs769953805, gnomAD rs769953805, REVEL 0.07, MetaLR 0.16
- R116W (p.Arg116Trp), TOPMed rs1338958161, gnomAD rs1338958161, REVEL 0.18, MetaLR 0.16, Uncertain significance, Agammaglobulinemia 10, autosomal dominant
- C118F (p.Cys118Phe), cosmic curated COSV99909, REVEL 0.05, MetaLR 0.06
- L119F (p.Leu119Phe), Ensembl rs1565637989, REVEL 0.02, MetaLR 0.05
- Q120K (p.Gln120Lys), cosmic curated COSV57045, REVEL 0.02, MetaLR 0.07
- Y121* (p.Tyr121Ter), rs2095916574, ClinGen CA380351832, ClinVar RCV001822090, ClinVar RCV005232672, AlphaMissense 0.95, MetaLR 0.38, Pathogenic
- Y121R (p.Tyr121Arg), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- P122T (p.Pro122Thr), TOPMed rs1417095568, gnomAD rs1417095568, REVEL 0.14, MetaLR 0.28
- L124P (p.Leu124Pro), NCI-TCGA Cosmic COSV5704, cosmic curated COSV57048, REVEL 0.14, MetaLR 0.07, Variant assessed as somatic; moderate impact.
- S125P (p.Ser125Pro), cosmic curated COSV57046, REVEL 0.06, MetaLR 0.13
- S125T (p.Ser125Thr), NCI-TCGA Cosmic COSV5704, NCI-TCGA Cosmic COSV9990, cosmic curated COSV99908, REVEL 0.07, MetaLR 0.11, Variant assessed as somatic; moderate impact.
- P126T (p.Pro126Thr), cosmic curated COSV99908
- A127D (p.Ala127Asp), TOPMed rs1325897682, gnomAD rs1325897682, REVEL 0.03, AlphaMissense 0.26, Uncertain significance, not specified
- Q128E (p.Gln128Glu), gnomAD rs1437805137
- Q128K (p.Gln128Lys), gnomAD rs1437805137, REVEL 0.12, MetaLR 0.10, Benign, Agammaglobulinemia
Public SPI1 analysis runs
- SPI1 analysis run — SPI1 (595 variants) — completed 2026-08-20